Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Mateon Therapeutics — Investor Presentation (October 2019)
30 slides from Oncotelic Therapeutics's investor presentation, Oct 9, 2019
Slide 1: Building the next generation Biotech: The Three Convergents
— SSF ONCOTELIC Building the next generation Biotech THE THREE CONVERGENTS MATEON THERAPEUTICS
Slide 2: Forward-looking Statements
Forward-looking Statements = This document contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in t
Slide 3: The Founders - Bringing together Tech and Biotech
— The Founders- Bringing together Tech and Biotech “+ Vuong Trieu- Founder of Oncotelic which recently acquired Mateon. Successfully repositioned old and/or failed drugs into billion dollar drugs. “+ Abraxane- reformulated paclitaxel with > 1B in annual sales ** Cynvilog- repositioned as next genera
Slide 4: The Three Convergents
a The Three Convergents Building the next generation biotech focusing on speed and efficiency Drug development is a lengthy, expensive and high risk process not amenable to rare disease or single individual disease Every NCE has its own safety issues which could derailed the entire clinical program
Slide 5: The AI Blockchain Supercomputing
— ~LlLNe ONCOTELIC SP 2. THE Al BLOCKCHAIN SUPERCOMPUTING MATEON THERAPEUTICS
Slide 6: Explosion of unstructured data requires AI
Explosion of unstructured data requires Al —— fia Se: Video, Images, Audio, natural language, TV, Emails, social media Unstructured data will account for more than 80% of the data unstructured collected by organizations [DC ond Ene proce tatdats will grow to 40 ZB by 2020, structured 2010 2020 1yyO
Slide 7: Knowledge Synthesis machine
an Knowledge Synthesis machine Actionable drug development Unstructured Data Scientific Literature Patents Disease Symptoms Clinical Trial Structured Data Clinical Trials Cohort selection Patient tracker Reporting Synthesis Pharmaceutical Information Jb PointR BRICK iki Patient & Provider Informatio
Slide 8: Low footprint AI computer
100W low footprint computer replaces racks of servers for data orchestration and coordination with data center Reduced Size hub of Al accelerator cluster for efficient localized cluster compute 30W fan-less compute hub of Al accelerator cluster connects wirelessly to provide an Al mesh fabric Reduce
Slide 9: The power performance disruption
The power performance disruption Specs Equals — 11x Xeon 2790v4 CPU 6 Al Accelerators Dell r730 servers Cluster Processing 100 Watts Peak ane | 1/100* power 9 Teraflops @16-bit SS . LL PCle Fabric | 1/20" price @10Gbps DMA That’s 11 Dell servers MATEON THERAPEUTICSY
Slide 10: AI: navigation through total knowledge
Al: navigation through total knowledge Match Pt to Drug ft Match Disease to Drug Data | Clinical Trial Design Live Trial tat t A é ‘ Post t Marketing ry we Placing Al/Supercomputing within reach of the entire organization % Real World Data- Electronic health records (EHRs)/ Claims and billing activi
Slide 11: Smart Protocol BlockChain: Efficiency in Execution
So ae Smart Protocol BlockChain: Efficiency in Execution Manufacturer cant | Smart Contact ape O Retailer \ Logistics Blockchain Node DP Blockchain Node = saraeaEE erie | oe | = Shared . ees i Ledger ledger is maintained = by all parties Wholesaler Blcckchain Node Blecichain Nede cent | Smart Contra
Slide 12: Antisense Platform
— ~LlLNe ONCOTELIC SP 2. ANTISENSE PLATFORM MATEON THERAPEUTICS
Slide 13: Antisense as Next Generation Drugs
a Antisense as Next Generation Drugs Attribute History Molecular weight Identification of clinical candidate Probability of identifying drug candidate Routes of administration Small Molecules 1850s to present 200-500 Random screening Low-~5% Oral, injectable, inhaled mAb 1920s to present >150,000 Fo
Slide 14: Antisense Oligonucleotide Molecules
DNA — Antisense Oligonucleotide Molecules Transcniptior e > > Single stranded (13- to 25-mer) DNA molecules (oligodeoxynucleotides) > Specifically inhibit target protein expression via complementary hybridization to relevant mRNA 5, -3' Antisense oligonucleotide 3 Target mRNA | * RNAse H-mediated cl
Slide 15: Oligonucleotide Chemistry 101
ae SSS LE — ‘Oligonucleotide Chemistry 101’ a " ol Ne “sae ° ° N. Vl N A Cy q el Hy fH Cr | { o=P—o., oSaae: \ & if oO. s i Se Phosphodiester Fa. H i bonds { «=e ( Come. Phosphorothioate bonds Xe ys * higher resistance to nucleases (< stability) MATEON THERAPEUTICS 15 15
Slide 16: FDA has approved several ASO
——_ we FDA has approved several ASO *¢1) Fomivirsen: for treatment of patients with cytomegalovirus (CMV) retinitis **2) Macugen: for age-related macular degeneration (AMD) of the retina *¢3) Mipomersen: for homozygous familial hypercholesterolemia (HOFH) 4) Nusinersen/Spinraza- for spinal muscular
Slide 17: Proper Applications of Antisense - Lessons Learned
———— ES ET EEE ae . . . _ Proper Applications of Antisense- Lessons Learned = Specificity: Antisense because of its specificity is not suitable in cases where cross inhibition of multiple targets are needed. This is the case for signaling molecules such as kinase inhibitors. Due to crosstalk it is d
Slide 18: TGF-Beta
— ~LlLNe ONCOTELIC SP 2. TGF-BETA THERAPEUTICS MATEON THERAPEUTICS
Slide 19: TGF-B
TGF-B progression of various tumors by inducing proliferation, metastasis, angiogenesis, and immunosuppression “+ Interest in anti-TGF-B therapeutics has remained high since 2000 “ Several recent high-profile deals reflect strong market interest * Therefore, reducing TGF-B2 expression has a very hig
Slide 20: Cancer - Current Landscape
cancer Cancer- Current Landscape : = ** In 2015- cancer death increased globally to 8.8 million of the 55.8 million deaths- or 1 of every 6 deaths. * In 2035- cancer death and new cases are projected to be 14.6 million and 24 million respectively. AACR Cancer Progress Report 2018 “+ Although the rob
Slide 21: TGF-B Self Immunization Protocol (SIP) - Oncotelic Invention
TGF-8 Self Immunization Protocol (SIP©) - Oncotelic Invention oe % Q ts TGF-B inhibitor (i.e. OT-101) lifts the immunosuppression and primes the innate immunity against the tumor. Once the body recognizes the cancer as foreign everything Xenogenization CTL- Cx] + Proliferation Exocytosis of Granules
Slide 22: Optimal Sequencing for TGF-B Self Immunization Protocol
Optimal Sequencing for TGF-8 Self Immunization Protocol Proper Sequencing is key to optimal immunotherapy 1. Expand immune reserve through IL-2 treatment or infusion of immune cells 2. Prime immune response with TGF-B inhibitor- OT-101 3. Boost immune response with chemotherapy 4. Revitalize the exh
Slide 23: OT-101: Drug Product - TGF-B2 Antisense
OT-101: Drug Product- TGF-B2 Antisense. . ** Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-B2 messenger RNA Ready for registration trials--Over 200 patients treated across 6 clinical trials Potential for breakthrough design
Slide 24: TGF-B2 Specific Antisense - Safety
— oo TGF-82 Specific Antisense- Safety : Name Target Expected Tox (Genetic models) Curre! ‘velopment Status TGF-8 ligand inhibitors- Impossible to achieve target specificity due to high homology between isoforms (except for jantisense) Inflammation and wasting (Azhar et al., 2009, LY2382770/Eli Lill
Slide 25: Single Agent Activity - Glioblastoma
ee Single Agent Activity- Glioblastoma: = G004-Phase 2b trial Title: A multi-national, multi-center, open-label, active-controlled, randomized parallel-group dose-finding study to evaluate the efficacy and safety of two doses of OT-101 in adult patients with recurrent high- grade glioma, administere
Slide 26: Clinical Efficacy: Objective Responses
Clinical Efficacy: Objective Responses A Tumor Vo fo “ Objective responses were observed among the 87 evaluable patients treated with OT-101: Best Objective Responses were: 5 CR (5.9%), 14 PR (16.5%), 28 SD (31.8%), and 40 PD (45.9%) Confirmed Best Objective Responses were: 4 CR (4.7%), 12 PR (12.9%
Slide 27: Single Agent Activity - Pancreatic Cancer
Single Agent Activity- Pancreatic Cancer P001- Phase 1/2 Clinical Trial Title: An Open-Label, Multicenter Dose-escalation Study to Evaluate the Safety and Tolerability of OT- 101 (TGF-82-specific Phosphorothioate Antisense Oligodeoxynucleotide), Administered Intravenously in Adult Patients with Adva
Slide 28: P001 Phase 1/2 Trial
— P001 Phase 1/2 Trial Patient 1006: CR as far out as 77 mos Percent survival Surgery: Whipple’s procedure 15 line: 5-FU/LV, Dose 425 mg/m2 24 line: 5-FU/LV, Dose 2600 mg/m2/24hr 34 line: Gemcitabine, Dose 1000 mg/m2/week OT-101- Liver mets/ Complete Response (Black Line) =—® Liver Mets =“ Liver+Oth
Slide 29: Pipeline Built Around the Three Convergents
Pipeline Built Around the Three Convergents Al/BlockChain back office support. The enginge driving the pipeline. 1) Discovery 2) Manufacturing 3) Clinical Pie = <a SE SM A OT-101 + TMZ *Available through Expanded Access Program together with Widetrial —{y “——~ WIDETRIAL Brain Cancer na/ OT-101* + So
Slide 30: Thank You
nn 7 SS Mateon/Oncotelic- (MATN)- Building The Next Gener Pharma iar ——@ ~iS™ NAVIGATOR DATA PIPELINE. Large Data Analytics Large Clinical Data High Value Pipeline MATEON 30 Thank You . THERAPEUTICS
Mateon Therapeutics — Investor Presentation (October 2019) on 6ix